Modality
ADC
MOA
CAR-T BCMA
Target
IL-23
Pathway
Epigenetic
Breast CaCKDIgAN
Development Pipeline
Preclinical
~Mar 2017
→ ~Jun 2018
Phase 1
Sep 2018
→ Jul 2029
Phase 1Current
NCT04262682
357 pts·IgAN
2023-06→2027-06·Active
NCT06205625
2,510 pts·CKD
2018-09→2029-07·Recruiting
2,867 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-06-211.2y awayInterim· IgAN
2029-07-273.3y awayInterim· CKD
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q4
P1
Recruit…
P1
Active
Catalysts
Interim
2027-06-21 · 1.2y away
IgAN
Interim
2029-07-27 · 3.3y away
CKD
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04262682 | Phase 1 | IgAN | Active | 357 | ORR |
| NCT06205625 | Phase 1 | CKD | Recruiting | 2510 | Safety |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| NVO-9087 | Novo Nordisk | Phase 1/2 | Tau | |
| DSN-6862 | Daiichi Sankyo | Preclinical | IL-23 | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| Tezecilimab | Regeneron | Approved | IL-23 | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| JAZ-8729 | Jazz Pharma | Phase 2/3 | FcRn | |
| Fixalucimab | Innovent Bio | Phase 1/2 | IL-23 |